

**Pioglitazone protected against cardiac hypertrophy via inhibiting
AKT/GSK-3 β and MAPK signaling pathways**

Wen-Ying Wei*, Zhen-Guo Ma*, Si-Chi Xu, Ning Zhang, Qi-Zhu Tang

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China
Cardiovascular Research Institute of Wuhan University, Wuhan, China

Corresponding author: Qi-Zhu Tang, Department of Cardiology, Renmin Hospital of Wuhan University; Cardiovascular Research Institute, Wuhan University at Jiefang Road 238, Wuhan 430060, China. E-mail: qztang@whu.edu.cn

*These authors contributed equally to this work.

Short title: Pioglitazone against cardiac hypertrophy

SUPPLEMENTAL FIGURES AND FIGURE LEGENDS:

Supplemental Figure S1




Figure S1. Effects of PIO on cardiac hypertrophy. Mice subjected to AB were given PIO (1 mg/kg, 2.5 mg/kg or 5 mg/kg) treatment for 3 weeks. Statistical results of heart weight (HW)/ body weight (BW) in the indicated groups (n=5).